Ricevi le ultime notizie sulle azioni Soligenix con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SNGX

Ultime notizie per

Soligenix

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix Inc

Press Releases

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Small Cap

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

News

Loop Industries (Nasdaq: LOOP) Unveils Game-Changing Twist™ Polyester Made Entirely from Textile Waste – More Stocks Inside

Opinion

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

Health Care

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy

General

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

AMGN

CTOR

FOLD

INSM

LOOP

SNGX

SNYR

TNXP

VRME

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AIM ImmunoTech

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

Aptevo Therapeutics

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Genprex

HCW Biologics

iBio

Immuron Limited - American Depositary Shares

Immuron

IN8bio

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Alliance Global Partners

Screenshot 2025-05-02 at 5.43.08 PM

Biotech

Soligenix Issues Interim Results For CTCL Treatment Trial – 75% Response At 18 Weeks, 3 Patients Achieve Complete Response

Screenshot 2025-04-23 at 10.53.10 PM

Soligenix&#39;s HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding

Screenshot 2025-02-24 at 11.30.54 PM

Interview

Soligenix Aims To Push The Boundaries In Treating Rare Diseases

Screenshot 2025-02-20 at 6.32.00 PM

Soligenix&#39;s Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026

Screenshot 2025-02-18 at 6.39.51 PM

Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behçet&#39;s Disease

Screenshot 2025-01-16 at 7.00.06 PM

Soligenix Targets Psoriasis With New Therapy

Screenshot 2024-12-16 at 6.43.37 PM

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL

Screenshot 2024-11-26 at 8.32.36 PM

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs

Comments

Soligenix Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO